<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473561</url>
  </required_header>
  <id_info>
    <org_study_id>RACE3002</org_study_id>
    <nct_id>NCT03473561</nct_id>
  </id_info>
  <brief_title>Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea</brief_title>
  <official_title>Efficacy and Safety of Racecadotril in the Treatment of Children Aged 3 to 60 Months Suffering From Acute Diarrhea: A Controlled Randomized, Open-label, Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Racecadotril in the treatment of children aged 3 to 60 months
      suffering from acute diarrhea: A controlled randomized, open-label, parallel-group study
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of diarrhea (hours) between the start of treatment until last diarrheal/watery stool before recovery or end of study treatment (treatment duration maximal 5 days</measure>
    <time_frame>5 days</time_frame>
    <description>Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of recovered subjects per treatment group</measure>
    <time_frame>5 days</time_frame>
    <description>Number of recovered subjects per treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Physician Assessment at the end of treatment</measure>
    <time_frame>5 days</time_frame>
    <description>scores 1-6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Diarrhea, Infantile</condition>
  <arm_group>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racecadotril plus ORS</intervention_name>
    <description>Racecadotril plus ORS</description>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORS</intervention_name>
    <description>ORS</description>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from one of the parent(s)/legal representative(s)

          -  Subjects, both genders, aged 3 to 60 months

          -  Subjects with acute diarrhea (defined as the passage of three or more unformed or
             liquid stools within the last 24 hours and lasting for less than 3 days)

        Exclusion Criteria:

          -  Known allergy to Racecadotril or any of its ingredients

          -  Subjects suffering from renal or hepatic impairment

          -  Subjects with fever &gt; 39 degrees Celsius

          -  Subjects with bloody and/or purulent stools

          -  Subjects suffering from antibiotic (e.g. amoxicillin)-associated diarrhea, chronic
             diarrhea or iatrogenic diarrhea

          -  Subjects with alternating bouts of diarrhea and constipation

          -  Diarrhea due to exacerbation of chronic gastrointestinal diseases such as irritable
             bowel syndrome, irritable bowel disease or pancreatic exocrine insufficiency

          -  Cystic fibrosis or coeliac disease

          -  Subjects suffering from prolonged or uncontrolled vomiting

          -  Subjects with rare hereditary problems of fructose intolerance, glucose-galactose
             malabsorption syndrome or sucrase isomaltase insufficiency

          -  Subjects having received antibiotic treatment at any time within 2 weeks prior to
             inclusion into the study

          -  Subjects having received antidiarrheal drugs 48 hours prior to inclusion into the
             study

          -  Subjects with severe dehydration requiring intravenous fluid, electrolyte replacement
             or hospitalization treatment

          -  Subject with a history of angioedema or who had reported angioedema with angiotensin
             converting enzyme inhibitors (such as captopril, enalapril, lisinopril, perindopril,
             ramipril)

          -  Subjects with combined diseases or medical situations that would prevent to be
             enrolled into the study, depending on the judgment of the investigator

          -  Intake of experimental drug within 30 days prior to study start

          -  Subjects with contraindications to ORS or susceptible to the warnings of ORS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suntje Sander, PhD</last_name>
    <phone>+49 511 6750</phone>
    <phone_ext>3254</phone_ext>
    <email>suntje.sander@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Children's Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng-Hsun Chiu, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Diarrhea, Infantile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Racecadotril</mesh_term>
    <mesh_term>Thiorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

